Evidence map›Paper›PMID 28053669›Full record

ArticleGut pathogens2017

Samin Zamani, Mohammad Reza Zali, Hamid Asadzadeh Aghdaei, Leonardo Antonio Sechi, Magdalena Niegowska, Elisa Caggiu, Rouhollah Keshavarz, Nader Mosavari, Mohammad Mehdi Feizabadi

Open access · goldAbstract read
In one paragraph

Article in Gut pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. ViableMicroorganisms · 2023
    Article
  8. Which bacterial toxins are worthy of validation as markers in colorectal cancer screening? A critical review.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2022
    Review
  9. Frontiers in cellular and infection microbiology · 2022
    Article
  10. Gut Serpinome: Emerging Evidence in IBD.International journal of molecular sciences · 2021
    Review
  11. Article
  12. Article
  13. Review
  14. DNA-based detection ofAIMS microbiology · 2021
    Article
  15. Article
  16. Microorganisms · 2020
    Article
  17. Article
  18. Genomic Detection ofIranian journal of medical sciences · 2020
    Article
  19. Potential Vaccines for Treating Crohn's DiseaseIranian biomedical journal · 2020
    Review
  20. Presence ofMicroorganisms · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Samin ZamaniDepartment of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Reza ZaliGastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran ; Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hamid Asadzadeh AghdaeiGastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran ; Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Leonardo Antonio SechiDepartment of Biomedical Sciences, University of Sassari, Viale San Pietro 43b, 07100 Sassari, Italy.
Magdalena NiegowskaDepartment of Biomedical Sciences, University of Sassari, Viale San Pietro 43b, 07100 Sassari, Italy.
Elisa CaggiuDepartment of Biomedical Sciences, University of Sassari, Viale San Pietro 43b, 07100 Sassari, Italy.
Rouhollah KeshavarzPPD Tuberculin Department, Razi Vaccine & Serum Research Institute, Karaj, Iran ; Reference Laboratory for Bovine Tuberculosis, Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization (AREEO), Tehran, Iran.
Nader MosavariPPD Tuberculin Department, Razi Vaccine & Serum Research Institute, Karaj, Iran ; Reference Laboratory for Bovine Tuberculosis, Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization (AREEO), Tehran, Iran.
Mohammad Mehdi FeizabadiDepartment of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran ; Thoracic Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
University of Sassari · ITRazi Vaccine and Serum Research Institute · IRShahid Beheshti University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory bowel disease (IBD) is described as a relapsing condition with high morbidity and uncertain complex pathogenesis. The association of

methodsAnti-MAP antibodies were detected in serum of IBD patients and subjects without IBD (nIBD) through ELISA; MAP DNA and viable MAP cells were identified in patients' biopsies through nested PCR and direct culture methods, respectively. Principal component analysis (PCA) was used to investigate the risk factors in relation to IBD and MAP infection.

resultsPositivity for IS900 PCR was detected in 64% (n = 18) of CD, 33% (n = 10) of ulcerative colitis (UC) and 9.7% (n = 6) of nIBD samples. Live MAP cells were isolated from biopsies of 2 CD patients only. Among 28 patients with CD, 46% (n = 13) and 39% (n = 11) were positive for antibodies against MAP3865c

conclusionsThis study provided evidences that high prevalence of MAP DNA and anti-MAP antibodies in CD patients is significantly associated with the development of CD. Despite the role of several factors contributing to IBD, the presence of MAP DNA and anti-MAP antibodies in Iranian CD patients highlights a possible transmission of MAP from animal-derived products to humans.

Indexed as

Crohn’s diseaseELISAInflammatory bowel diseaseIranIS900 nested PCRMycobacterium avium subsp. paratuberculosis

Identifiers

PMID28053669
PMCPMC5209900
OpenAlexW2562723528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.